The Disruptive Technologies Innovation Fund, a major driver of Impact 2030 research and innovation strategy, has awarded Amara Therapeutics funding for RiSolve - a safe and effective personalised therapy that will disrupt the overactive bladder treatment market using an innovative artificial intelligence-based digital platform.
Read the Departmental Press Release
Read more on Silicon Republic